When Will Fondaparinux Induce Thrombocytopenia?
Open Access
- 25 July 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 33 (8) , 1574-1583
Abstract
The pentasaccharide Fondaparinux, a synthetic selective factor Xa inhibitor, is one of the safest anticoagulants in the heparin family that is recommended as an alternative drug for patients with hypersensitivity to other drugs such as heparin-induced thrombocytopenia (HIT). However, some observations of Fondaparinux-induced thrombocytopenia (FIT) have been reported while others claimed that FIT does not occur in patients with fondaparinux therapy, indicating that the mechanism of FIT remains controversial. Here, we utilized different methodologies including dynamic light scattering, immunosorbent and platelet aggregation assays, confocal laser scanning microscopy, and flow cytometry to gain insights into FIT. We found that at a certain concentration, Fondaparinux formed sufficient large and stable complexes with PF4 that facilitated binding of the HIT-like monoclonal KKO antibody and enhanced platelet aggregation and activation. We proposed a model to describe the role of Fondaparinux concentration in the formation of complexes with platelet factor 4 and how it promotes the binding of KKO. Our results clarify controversial observations of FIT in patients as each contains a dissimilar PF4:Fondaparinux concentration ratio.Keywords
Funding Information
- Th?ringer Ministerium f?r Wirtschaft, Wissenschaft und Digitale Gesellschaft
- Deutsche Forschungsgemeinschaft (469240103 and 269095734)
This publication has 50 references indexed in Scilit:
- Can heparin‐induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttalJournal of Thrombosis and Haemostasis, 2008
- Determinants of PF4/heparin immunogenicityBlood, 2007
- Heparin-Induced Thrombocytopenia Associated with FondaparinuxNew England Journal of Medicine, 2007
- Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT AntibodiesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implicationsBlood, 2006
- Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopeniaEuropean Journal of Haematology, 2006
- Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopeniaBlood, 2005
- Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agentExpert Opinion on Investigational Drugs, 2002
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Laboratory diagnosis of heparin‐associated thrombocytopenia and comparison of platelet aggregation test, heparin‐induced platelet activation test, and platelet factor 4/heparin enzyme‐linked immunosorbent assayTransfusion, 1994